We have shown that CD40L-overexpressing CAR T cells have an increased antitumor effect, license antigen-presenting cells (APCs) in vivo, activate endogenous T cells, and protect mice from CAR-antigen negative tumor challenge6. This evidence concerns the gene CD40LG and neoplasm.